• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Life Sciences companies face difficulties incorporating ESG into their compliance programs


Hogan Lovells released a survey that tracked the thinking of compliance professionals who are implementing ESG into compliance programs.

ESG (environmental, social and governance) has become a top compliance concern for life sciences companies around the world—yet the evidence suggests that many are struggling to embed ESG into their existing compliance programs.

A survey of compliance professionals at 100 multinational life sciences companies globally reveals an overwhelming majority—84%—report that ESG risk is increasing as a priority for their board. Yet more than four in five also report that the failure to embed ESG into existing risk practices is impeding their organization’s ESG risk management.

Hogan Lovells’ Navigating Deep Waters survey, released today, tracks the thinking of experienced compliance professionals who are integrating the social and governance aspects of ESG into existing compliance programs.

Read more about Hogan Lovell's survey here.

Related Videos
Related Content